All In Biotech

Drug Trial Radar · NCT00261911

A Study of Sibutramine in Overweight Adolescents to Assess Weight Loss and Safety.

A 12 Month Study to Assess Safety and Efficacy of Meridia (Sibutramine Hydrochloride Monohydrate) 10 and 15 mg in Obese Adolescents

Last checked: Nov 20, 2026Latest source record: Aug 31, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 498 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

498

Actual

Start

Jul 2000

Primary completion

Not stated

Study completion Feb 2002

Sponsor

Lead sponsor
AbbottIndustry
Sponsor type
Industry
First posted
Dec 6, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 16 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the effectiveness of sibutramine on weight loss, reduction in body size and improvement in metabolic risk factors and safety in obese adolescents.

Conditions

  • Obesity

Interventions

  • sibutramineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute change in body mass index (BMI) from baseline to endpoint.Time frame: 12 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.